VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Novel treatment strategies for patients with CML who are intolerant or resistant to available TKIs

Valentin Garcia Gutiérrez, MD, PhD, Hospital Universitario Ramón y Cajal, Madrid, Spain, discusses the necessity to develop novel treatment strategies for patients with chronic myeloid leukemia (CML) who are resistant or intolerant to available tyrosine kinase inhibitors (TKIs), commenting on asciminib and novel TKIs currently under investigation, as well as the possibility to combine TKIs with other agents. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding, speaking engagements, ad boards: Novartis, BMS, Incyte, Pfizer

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter